Reduction of pituitary tumor size with clinical and biochemical improvement with bromocriptine in a normoprolactinemic Cushing's disease.

We report a 37-year old Japanese female patient with Cushing's disease who was treated with a large daily dose of bromocriptine, which resulted in the reduction of the pituitary tumor size with clinical and biochemical improvements. On admission, the pituitary tumor size detected by magnetic resonance imaging (MRI) was 12.4 x 11.1 x 6.2 mm. Both the basal plasma prolactin level and its response to TRH test were normal. The patient was treated with bromocriptine at 5 to 35 mg/day. With 35 mg daily, 24-h urinary free cortisol started to decrease and eventually became normal. Four months after initiation of treatment with the drug, there was clinical remission with normalization of suppressibility of plasma cortisol with 1 mg dexamethasone. Repeated examination of the pituitary fossa by MRI showed a marked reduction in the tumor size (6.3 x 6.2 x 2.4 mm). This is a very rare case in which treatment with bromocriptine resulted in a reduction of the pituitary tumor size as well as clinical and biochemical improvements in a patient with normoprolactinemic Cushing's disease.

[1]  M. Vance,et al.  Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. , 1990, Annals of internal medicine.

[2]  D. Lüdecke,et al.  Necroses of prolactin-secreting pituitary adenomas under treatment with dopamine agonists: light microscopical and morphometric studies. , 2009, Experimental and clinical endocrinology.

[3]  A. Grossman,et al.  A BROMOCRIPTINE‐RESPONSIVE CORTICOTROPH ADENOMA SECRETING α‐MSH IN A PATIENT WITH CUSHING'S DISEASE , 1988, Clinical endocrinology.

[4]  J. Doppman,et al.  Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging. , 1987, Radiology.

[5]  T. H. Newton,et al.  Pituitary adenomas: high-resolution MR imaging at 1.5 T. , 1986, Radiology.

[6]  H. Mogami,et al.  Effects of bromocriptine on prolactin‐secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis , 1985, Cancer.

[7]  T. Fujita,et al.  Effect of ovine corticotrophin releasing factor, bromocriptine, and dopamine on release of ACTH and beta-endorphin in a patient with Cushing's disease. , 1985, Acta Endocrinologica.

[8]  中島 弘子.  Effect of ovine corticotrophin releasing factor, bromocriptine, and dopamine on release of ACTH and β-endorphin in a patient with Cushing's disease , 1985 .

[9]  C. Francalanci,et al.  Cushing’s disease: clinical and laboratory response to bromocriptine therapy , 1984, Journal of endocrinological investigation.

[10]  M. Tagliaferri,et al.  Cushing’s disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment , 1984, Journal of endocrinological investigation.

[11]  G. Giannattasio,et al.  Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. , 1984, The Journal of clinical endocrinology and metabolism.

[12]  M. Boscaro,et al.  EFFECT OF BROMOCRIPTINE IN PITUITARY‐DEPENDENT CUSHING'S SYNDROME , 1983, Clinical endocrinology.

[13]  W. Mcdonald,et al.  Bromocriptine in management of large pituitary tumours. , 1982, British medical journal.

[14]  A. Karle,et al.  Size reduction of extrasellar pituitary tumors during bromocriptine treatment. , 1982, Annals of internal medicine.

[15]  T. Yamaji,et al.  Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro. , 1981, The Journal of clinical investigation.

[16]  J. Birkenhäger,et al.  Effect of bromocriptine in pituitary-dependent Cushing's syndrome. , 1976, The Journal of endocrinology.

[17]  M. Ojima,et al.  Treatment of Cushing's disease with reserpine and pituitary irradiation. , 1975, The Journal of clinical endocrinology and metabolism.

[18]  F. H. Tyler,et al.  DIAGNOSIS OF CUSHING'S SYNDROME; SINGLE DOSE DEXAMETHASONE SUPPRESSION TEST. , 1965, Archives of internal medicine.

[19]  C. C. Porter,et al.  The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma. , 1954, The Journal of biological chemistry.